are glp-1 receptor agonists approved for type 1 diabetes fda increasingly used to treat 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read PDB-101: Molecule of the Month:

People with digestive disorders : Conditions like irritable bowel syndrome (IBS), Crohns disease, or celiac disease can impact nutrient absorption, which may result in lower glutathione production

Three liposomal formulas Creatine, NAD+, and Curcumin with Resveratrol targeting energy, power, and recovery together

People focused on skincare and anti-aging benefits

Reduced levels of nitric oxide contribute to vasoconstriction (blood vessel narrowing) and increased blood pressure

If a patient cannot maintain regular bowel movements, binder therapy must be paused or adjusted, as adding binders to a sluggish gut will only exacerbate systemic toxicity and inflammation

Yazici D, Sezer H